R&D Wilmington is located in Wilmington, Delaware, not far from Philadelphia. Research here is focused on pain control, neurology and psychiatry. The site is a centre of excellence in psychiatry, concentrating on developing therapies for schizophrenia, anxiety, depression, bipolar and dementia.

We employ over 2,000 people in R&D in Wilmington, which is also our US Corporate HQ with over 5,000 employees in total.

Zomig , Seroquel and Diprivan are innovations from our Wilmington laboratories.

Read more about this facility.